Turning a Targeting β-Catenin/Bcl9 Peptide Inhibitor into a GdOF@Au Core/Shell Nanoflower for Enhancing Immune Response to Cancer Therapy in Combination with Immune Checkpoint Inhibitors

Combination administration is becoming a popular strategy in current cancer immunotherapy to enhance tumor response to ICIs. Recently, a peptide drug, a protein–protein interaction inhibitor (PPI), that disrupts the β-catenin/Bcl9 interaction in the tumoral Wnt/β-catenin pathway has become a promisi...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Weiming, Ma, Fang, Zhang, Zhang, Yan, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228893/
https://www.ncbi.nlm.nih.gov/pubmed/35745877
http://dx.doi.org/10.3390/pharmaceutics14061306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228893/
https://www.ncbi.nlm.nih.gov/pubmed/35745877
http://dx.doi.org/10.3390/pharmaceutics14061306

Ejemplares similares